KOL Insight Archives | Page 13 of 14 | Report Store

2015 Breast Cancer Pulse #3

We performed a 5-question survey of 25 oncologists in the US to gauge current prescribing practices for breast cancer treatments.

June 12, 2015

Find out more

Ebola KOL Interview #3

$599.00

Ebola KOL Interview #3

December 2, 2014

Find out more

Post-AASLD US KOL Interview

$599.00

Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.

December 16, 2014

Find out more

2014 Community-Acquired Pneumonia Pulse

$599.00

We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates.

December 18, 2014

Find out more

Post-CHDI Huntington’s Disease KOL Interview

$799.00

Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

March 16, 2015

Find out more

Asthma and COPD KOL Interview

$599.00

KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

February 29, 2016

Find out more

Pneumococcal Vaccines KOL Interview

$599.00

Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

August 27, 2016

Find out more

ADPD Alzheimer’s Disease Pulse

$599.00

Overview We performed a 5-question survey of 25 neurologists in the US to gauge current familiarity with Alzheimer’s Disease (AD) biomarkers and drugs in clinical development for disease modification. Drugs covered include: BIIB037/BART (BIIB), Solanezumab (LLY), Pioglitazone (Takeda), BAN2401 (ESALY/BIIB), MK-8931 (MRK).

March 19, 2015

Find out more

Biosimilars and Reimbursement KOL Interview

$599.00

Topics: Biosimilars and Reimbursement

Physician Information

Specialty: Specialty Pharmaceuticals

Location: Alexandria, VA

July 31, 2015

Find out more

Pediatric Acute Leukemias (AML/ALL) KOL Interview

$599.00

Highlights Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients. CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications. Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely […]

April 1, 2015

Find out more

Post-ADPD Alzheimer’s Disease KOL Interview

$599.00

Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]

April 8, 2015

Find out more

Dyslipidemia and Diabetes Reimbursement KOL Interview:

$599.00

Topics: Dyslipidemia and Diabetes Reimbursement PCSK9 Inhibitors, SGLT2/DPP4 Inhibitor FDCs, and Biosimilar Insulin

August 5, 2015

Find out more

2015-cll-pulse-2-drug-usage-and-reimbursement

2015 Chronic Lymphocytic Leukemia (CLL) Pulse

$599.00

We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.

January 27, 2015

Find out more

MDS/AML KOL Interview

$599.00

Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

April 9, 2015

Find out more

2016 Biomedtracker ASCO Survey

$599.00

Biomedtracker performed a 5-question survey of 39 United States and European (France, Germany, Italy, and United Kingdom) oncologists after the American Society of Clinical Oncology (ASCO) meeting to gauge interest in new data presented on drugs in clinical development.

June 8, 2016

Find out more